Lodo Therapeutics
Lodo Therapeutics is a privately held drug discovery and development company founded in 2016 and headquartered in New York. Co-founded by Sean Brady, it operates with a small team and has expanded its therapeutic pipeline through the 2020 acquisitions of Conifer Point Pharmaceuticals and Hibiskus Biopharma.
- Company typePrivate
- Founded2016
- HeadquartersNew York, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Lodo Therapeutics does
Lodo Therapeutics is a privately held drug discovery and development company founded in 2016 and headquartered in New York. The company is co-founded by Sean Brady and operates with a small team of 1-10 employees, consistent with an early-stage, science-driven biotech focused on therapeutic discovery rather than commercial-scale operations.
On January 11, 2016, Lodo closed a $17,000,000 financing round backed by a high-quality syndicate of strategic and financial investors, including AbbVie, Eli Lilly, Pfizer Venture Investments, ARCH Venture Partners, WuXi AppTec, the Bill & Melinda Gates Foundation, Johnson & Johnson Robotics and Digital Solutions, Alexandria, Accelerator Life Science Partners, Empire State Development, Harris and Harris Group, the Partnership Fund for New York City, 180 Degree Capital, and the Watson Fund. The mix of large pharma strategics alongside tier-one life-sciences venture investors suggests a platform oriented toward eventual pharma collaboration or out-licensing.
In 2020, Lodo pursued an inorganic pipeline-buildout strategy, acquiring Conifer Point Pharmaceuticals on August 7, 2020 and Hibiskus Biopharma on September 3, 2020, both for undisclosed amounts. These back-to-back acquisitions indicate a focus on consolidating therapeutic assets rather than solely relying on internal discovery output. Beyond the firmographic profile, the 2016 financing, the 2020 acquisitions, and the co-founder relationship, the input data does not disclose specific product candidates, clinical-stage assets, partnerships, or revenue-generating activities.
Lodo Therapeutics firmographics
Firmographics- Name
- Lodo Therapeutics
- Website
- https://lodotherapeutics.com
- Company type
- Private
- Founded year
- 2016
- Headcount range
- 1–10 employees
- Short description
- Lodo Therapeutics is a privately held drug discovery and development company founded in 2016 and headquartered in New York. Co-founded by Sean Brady, it operates with a small team and has expanded its therapeutic pipeline through the 2020 acquisitions of Conifer Point Pharmaceuticals and Hibiskus Biopharma.
- Ownership category
- akta.pro rank
Lodo Therapeutics industry classification
Industry- Product category
- Drug Discovery and Development
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA)
- akta.pro secondary industry
- Engineered Microbial Therapeutics (synthetic biology, gene circuits) (HLAAAFAD)
Keywords
Where Lodo Therapeutics is headquartered
LocationHeadquarters
- HQ city
- New York
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Lodo Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Others
Revenue model
- Autonomous Lab Services: Ginkgo provides access to its autonomous laboratory infrastructure where experiments are run on behalf of clients. The Solutions and Datapoints teams work with clients to design and execute experiments addressing their specific R&D goals. This is a service-based model where Ginkgo conducts the experimental work and delivers results.
- Automation Product: Ginkgo offers products for building autonomous labs including hardware and software solutions, allowing organizations to build their own autonomous laboratory infrastructure.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom enterprise engagement |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels4 records
Lodo Therapeutics product offering
Product offeringCore offering
Lodo Therapeutics is a drug discovery and development company that identifies and develops novel therapeutic candidates based on microbial natural products. The company leverages proprietary microbial culture and biosynthetic screening technologies to discover small molecule drug leads from uncultured bacteria. Lodo has expanded its development pipeline through acquisitions of Hibiskus Biopharma and Conifer Point Pharmaceuticals.
Product overview
No product information available for Lodo Therapeutics in the provided source data. The source material contains information about Ginkgo Bioworks, a separate biotechnology company offering autonomous labs, cloud lab services, and biological design automation platforms. Since the source pertains to a different company, no products or services for Lodo Therapeutics can be extracted.
Differentiator
Problem solved
Functional benefit
Products and services
- Microbial Natural Product Drug Discovery Services
Quantifiable outcome
- Scientists empowered to focus on insight and creativity rather than manual lab work
Companies that use Lodo Therapeutics
Customer profileNamed customers10 records
Segments3 records
Ideal customer profiles1 record
Lodo Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Lodo Therapeutics partnerships and signals
Strategic signalScale indicators1 record
Recent moves3 records
Expansion highlights2 records
Lodo Therapeutics competitors and assessment
Company assessmentDirect peers
- Hexagon Bio: Hexagon Bio uses genomics, synthetic biology, and AI/ML to mine microbial genomes (fungi and bacteria) for novel drug-like molecules — the closest analog to Lodo's natural product discovery approach from uncultured microbial DNA.
- Vedanta Biosciences: Vedanta develops defined consortia of bacteria for therapeutic use, overlapping with Lodo's microbial therapeutic focus and pipeline expansion into disease-relevant bacterial programs.
- Federation Bio: Federation Bio engineers microbiome-based therapeutics with a synthetic biology platform — comparable to Lodo's microbial discovery and engineering capabilities.
- Second Genome: Second Genome uses microbiome science to discover and develop therapeutics, sharing Lodo's emphasis on microbial-derived drug discovery and development.
- Eligo Biosciences: Eligo Bio develops engineered microbiome-based therapeutics using synthetic biology — closely aligned with Lodo's microbial therapeutic platform and discovery approach.
- Locus Biosciences: Locus Biosciences engineers bacteriophage and microbial products for therapeutic use, overlapping with Lodo's microbial and infectious-disease therapeutic focus.
Broad incumbents
- Ginkgo Bioworks: Ginkgo operates a broad synthetic biology and autonomous lab platform with deep pharma partnerships across natural product discovery — a much larger incumbent addressing adjacent drug-discovery problems.
- AbCellera: AbCellera operates an AI-powered antibody discovery platform with major pharma partnerships, comparable as a broad biologics-discovery incumbent serving similar customer segments.
- Recursion Pharmaceuticals: Recursion applies AI and high-throughput experimental automation to drug discovery, pursuing a similar platform thesis at greater scale and capital intensity than Lodo.
- Insitro: Insitro combines machine learning with functional genomics for drug discovery, comparable as a well-capitalized AI-driven discovery platform targeting similar pharma partners and therapeutic areas.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat2 records
Key risks6 records
Key highlights6 records
Customer concentration
Lodo Therapeutics social profiles
Digital presenceLodo Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Lodo Therapeutics leadership team
Management profileNumber of profiles
Profiles1 record
Lodo Therapeutics funding detail
Funding detailFunding overview
Funding rounds1 record
Investors14 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Lodo Therapeutics M&A and investment
M&A and investmentM&A2 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Lodo Therapeutics
What does Lodo Therapeutics do?
Lodo Therapeutics is a drug discovery and development company that identifies and develops novel therapeutic candidates based on microbial natural products. The company leverages proprietary microbial culture and biosynthetic screening technologies to discover small molecule drug leads from uncultured bacteria. Lodo has expanded its development pipeline through acquisitions of Hibiskus Biopharma and Conifer Point Pharmaceuticals.
When was Lodo Therapeutics founded?
Lodo Therapeutics was founded in 2016. It employs 1 to 10 people.
Where is Lodo Therapeutics based?
Lodo Therapeutics is headquartered in New York, United States, in the North America region.
How does Lodo Therapeutics make money?
Two revenue lines are on record. Autonomous Lab Services are the primary driver. The others are automation Product.
Who are Lodo Therapeutics's main competitors?
Direct peers on record are Hexagon Bio, Vedanta Biosciences, Federation Bio, Second Genome, Eligo Biosciences and Locus Biosciences. Broad incumbents are Ginkgo Bioworks, AbCellera, Recursion Pharmaceuticals and Insitro.
Does Lodo Therapeutics have an API?
No public API is recorded for Lodo Therapeutics.
What industry is Lodo Therapeutics in?
Lodo Therapeutics's product category is Drug Discovery and Development. Its primary akta.pro industry code is HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery), with a secondary code of HLAAAFAD, Engineered Microbial Therapeutics (synthetic biology, gene circuits). Its NAICS code is 541714 and its SIC code is 8731.